4-(2-(苄基氨基)丙基)苯酚 | 27566-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-(苄基氨基)丙基)苯酚
• 英文名称: 4-(2-(benzylamino)propyl)phenol
• 英文别名: p-<2-(Benzylamino)propyl>phenol；p-[2-(Benzylamino)propyl]phenol；4-[2-[(Phenylmethyl)amino]propyl]phenol；4-[2-(benzylamino)propyl]phenol
• CAS: 27566-05-8
• 化学式: C₁₆H₁₉NO
• 分子量: 241.333
• InChiKey: OUKACZRGSBUQSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-(苄基氨基)丙基)苯酚 在 10% palladium on active carbon 甲酸 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、300.0 kPa 条件下， 反应 6.0h， 以60%的产率得到4-(2-氨基丙基)苯酚
  参考文献：
  名称：

  Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the β2-adrenergic receptor status in lung

  摘要：

  The F-18-labeled beta2-adrenergic receptor ligand (R,R)(S,S) 5-(2-(2-[4-(2-[F-18]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl) -benzene-1,3-diol, a derivative of the original highly selective racemic fenoterol, was synthesized in an overall radiochemical yield of 20% after 65 min with a radiochemical purity higher than 98%. The specific activity was in the range of 50-60 GBq/mumol. In vitro testing of the non-radioactive fluorinated fenoterol derivative with isolated guinea pig trachea was conducted to obtain an IC50 value of 66 nM. Preliminary ex vivo organ distribution and in vivo experiments with positron emission tomography (PET) on guinea pigs were performed to study the biodistribution as well as the displacement of the radiotracer to prove specific binding to the beta2-receptor. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00538-9
• 作为产物：
  描述：

  1-(4-甲氧苯基)-2-苄胺基丙烷 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到4-(2-(苄基氨基)丙基)苯酚
  参考文献：
  名称：

  Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors

  摘要：

  A novel series of formoterol-phthalazinone hybrids were synthesised and evaluated as dual pharmacology beta(2)-adrenoceptor agonists and PDE4 inhibitors. Most of the hybrids displayed high beta(2)-adrenoceptor agonist and moderate PDE4 inhibitory activities. The most potent compound, (R, R)-11c, exhibited agonist (EC50 = 1.05 nM, pEC(50) = 9.0) and potent PDE4B2 inhibitory activities (IC50 = 0.092 mu M). (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.11.028

文献信息

• A Bioinspired Synthesis of Polyfunctional Indoles
  作者：Zheng Huang、Ohhyeon Kwon、Haiyan Huang、Aziz Fadli、Xavier Marat、Magali Moreau、Jean-Philip Lumb

  DOI：10.1002/anie.201806490

  日期：2018.9.10

  Polyfunctional indoles bearing substituents at C5 and C6 are prevalent in natural products, pharmaceuticals, agrochemicals, and materials. Owing to the remoteness of the C5 and C6 positions, indoles of this family can be difficult to prepare, and often require multistep syntheses. Herein, we describe a concise process that converts simple derivatives of tyrosine into 5,6‐difunctionalized indoles by

  在天然产物，药物，农用化学品和材料中普遍存在在C5和C6处带有取代基的多官能吲哚。由于C5和C6位置偏僻，该家族的吲哚可能难以制备，并且通常需要多步合成。在这里，我们描述了一个简单的过程，该过程通过将C，H，NH和OH键直接氧化，将酪氨酸的简单衍生物转化为5,6-双官能化的吲哚。我们的工作从酪氨酸的生物合成聚合制取黑色素颜料中获得了灵感，但为提供定义明确的吲哚杂环化合物进行了重要的改进。
• [EN] DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST<br/>[FR] DIARYLE ETHERS UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEUR OPIOIDES
  申请人：LILLY CO ELI

  公开号：WO2004026305A1

  公开（公告）日：2004-04-01

  A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  公式（I）的化合物，其中变量X1至X10，R1至R7包括R3'，E，v，y，z，A和B如所述，或其药用盐，溶剂化物，对映体，消旋体，非对映异构体或其混合物，用于治疗、预防或改善肥胖和相关疾病。
• Saligenin analogs of sympathomimetic catechol amines
  作者：David T. Collin、David. Hartley、David. Jack、Lawrence H. C. Lunts、J. C. Press、Alexander C. Ritchie、Paul. Toon

  DOI：10.1021/jm00298a022

  日期：1970.7.1
• Schirrmacher, E.; Schirrmacher, R.; Buhl, R., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S436 - S438
  作者：Schirrmacher, E.、Schirrmacher, R.、Buhl, R.、Wessler, I.、Machulla, H.-J.、Roesch, F.

  DOI：——

  日期：——
• de Antoni; Eche; Guillemot, European Journal of Medicinal Chemistry, 1978, vol. 13, # 6, p. 545 - 552
  作者：de Antoni、Eche、Guillemot、et al.

  DOI：——

  日期：——